The trajectory of the erectile dysfunction drug presents a complex picture for shareholders. While the initial launch generated massive profits, the expiration of its patent opened the door to off-brand competitors, https://bookmarkquotes.com/story21773229/sildenafil-and-the-pharmaceutical-industry-a-precarious-opportunity